Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY2874455 |
Synonyms | |
Therapy Description |
LY2874455, a pan-FGFR inhibitor, has equivalent potency against FGFR1-4 and inhibits FGF/FGFR mediated signaling to reduce tumor growth (PMID: 21900693). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY2874455 | FGFR Inhibitor (Pan) 26 | LY2874455, a pan-FGFR inhibitor, has equivalent potency against FGFR1-4 and inhibits FGF/FGFR mediated signaling to reduce tumor growth (PMID: 21900693). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 over exp | Advanced Solid Tumor | sensitive | LY2874455 | Preclinical | Actionable | In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693). | 21900693 |
FGFR3 V555M | Advanced Solid Tumor | sensitive | LY2874455 | Preclinical - Cell culture | Actionable | In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880). | 28034880 |
FGFR3 N540K | Advanced Solid Tumor | decreased response | LY2874455 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880). | 28034880 |
FGFR3 L608V | Advanced Solid Tumor | sensitive | LY2874455 | Preclinical - Cell culture | Actionable | In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). | 28034880 |
FGFR3 K650E | Advanced Solid Tumor | sensitive | LY2874455 | Preclinical - Cell culture | Actionable | In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880). | 28034880 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|